DTX2P1-UPK3BP1-PMS2P11

Mutation & survival
SurvivalMutationKaplan–Meier · TCGA cohorts

Across TCGA pan-cancer cohorts, DTX2P1-UPK3BP1-PMS2P11 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated DTX2P1-UPK3BP1-PMS2P11 data layer compared with 20 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher DTX2P1-UPK3BP1-PMS2P11 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated DTX2P1-UPK3BP1-PMS2P11 expression acts as an unfavorable survival marker.

STAD are the cancer types where DTX2P1-UPK3BP1-PMS2P11 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.
LineageMeasureSplitStageAUC1
high
AUC2
low
pSampling consensus
STADOSMedianAll0.1220.690<.00141view →
Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

DTX2P1-UPK3BP1-PMS2P11–STAD (OS)

Kaplan–Meier survival curve for DTX2P1-UPK3BP1-PMS2P11 mutant vs wild-type samples in STAD.

Open the STAD breakdown →

Exploration